BioSpace News Archive

Amgen will present at the Evercore ISI HealthCONx Conference at 9:10 a.m. EST on Wednesday, Nov. 29, 2023.

Aeglea BioTherapeutics, Inc. announced that Aeglea’s independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 351,750 shares of common stock and a grant of 18,912 restricted stock units to four non-executive employees as equity inducement awards under the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan, as amended.

Shanghai Junshi Biosciences Co., Ltd announced a new publication in the Lancet Infectious Diseases.

EirGenix Inc. announced that its trastuzumab biosimilar medicine which their commercial partner Sandoz plans to commercialise had received a marketing authorization from the European Commission.

AlzeCure Pharma AB announced that the company is participating at Aktiespararna’s event Stora Aktiedagarna i Stockholm on November 27 at 14:20 CET, where CEO Martin Jönsson will present and answer questions about the latest developments and the company’s plans going forward.

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 8:20 AM ET on November 29 at the Evercore ISI HealthCONx Conference, taking place November 28-30, 2023, in Miami, Florida.

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and technology industries, announced that the company will host an Investor Day on December 8, 2023, at 9:00 a.m. Eastern Standard Time and concluding at approximately 12:00 p.m.

People with long COVID exhibit patterns of changes in the brain that are different from fully recovered COVID-19 patients, according to research being presented next week at the annual meeting of the Radiological Society of North America.

Satellos Bioscience Inc. announced today its financial results and operational highlights for the three months ending September 30, 2023. All references to currency in this press release are in Canadian dollars unless otherwise noted.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2023.